News > Explained: Tocilizumab reduces death risk in severely ill Covid patients, trial in India finds

Explained: Tocilizumab reduces death risk in severely ill Covid patients, trial in India finds

A phase 3 trial in India has found tocilizumab improves outcomes in severely ill Covid-19 patients, reviving the debate over the anti-inflammatory drug that is used primarily to treat rheumatoid arthritis. 

While suggesting that tocilizumab may help severely ill patients, the authors also noted that the study does not support the routine use of tocilizumab in adults with Covid-19.